In yesterday’s Wall Street session, Biofrontera Inc. (NASDAQ:BFRI) shares traded at $1.00, unchanged from the previous session.
BFRI stock price is now -8.17% away from the 50-day moving average and -55.22% away from the 200-day moving average. The market capitalization of the company currently stands at $25.40M.
A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BFRI stock. A new stake in Biofrontera Inc. shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $14,000. JANE STREET GROUP, LLC invested $10,000 in shares of BFRI during the first quarter. In the first quarter, TOWER RESEARCH CAPITAL LLC (TRC) acquired a new stake in Biofrontera Inc. valued at approximately $9,000. UBS GROUP AG acquired a new stake in BFRI for approximately $5,000. In total, there are 19 active investors with 10.50% ownership of the company’s stock.
Monday morning saw Biofrontera Inc. (NASDAQ: BFRI) opened at $0.9900. During the past 12 months, Biofrontera Inc. has had a low of $0.82 and a high of $14.63. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.20, and a quick ratio of 2.60. The fifty day moving average price for BFRI is $1.0889 and a two-hundred day moving average price translates $2.2329 for the stock.
The latest earnings results from Biofrontera Inc. (NASDAQ: BFRI) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.05, beating analysts’ expectations of -$0.34 by 0.29. This compares to -$0.46 EPS in the same period last year. The net profit margin was -93.10% and return on equity was -360.80% for BFRI. The company reported revenue of $4.46 million for the quarter, compared to $5.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -23.88 percent. For the current quarter, analysts expect BFRI to generate $4.31M in revenue.
Biofrontera Inc.(BFRI) Company Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company’s licensor’s medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.